1-(4-fluorophenyl)-4-pyrrolo[1,2-c]pyrimidin-4-yl-pyrazolo[3,4-b]pyridine

ID: ALA5287872

Max Phase: Preclinical

Molecular Formula: C19H12FN5

Molecular Weight: 329.34

Associated Items:

This compound is not in our inventory system

Names and Identifiers

Canonical SMILES:  Fc1ccc(-n2ncc3c(-c4cncn5cccc45)ccnc32)cc1

Standard InChI:  InChI=1S/C19H12FN5/c20-13-3-5-14(6-4-13)25-19-17(11-23-25)15(7-8-22-19)16-10-21-12-24-9-1-2-18(16)24/h1-12H

Standard InChI Key:  ZPSJYNRBQSWYJB-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 25 29  0  0  0  0  0  0  0  0999 V2000
   -1.2339    1.0307    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2355    0.2057    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9507   -0.2053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5217   -0.2080    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1934    0.2030    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.1949    1.0280    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.5187    1.4419    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.8110   -0.3692    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.4790   -1.1031    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3447   -1.0092    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.6081   -0.1557    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8220    0.6413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6169    0.8536    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2006    0.2699    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9896   -0.5236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1941   -0.7417    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9977    0.4835    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   -1.9521   -1.0306    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6676   -1.4419    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3815   -1.0280    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.3800   -0.2027    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.6646    0.2085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9977    0.3697    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.6657    1.1037    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8416    1.0098    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  2  4  1  0
  4  5  2  0
  5  6  1  0
  6  7  2  0
  7  1  1  0
  5  8  1  0
  8  9  1  0
 10  9  2  0
  4 10  1  0
  8 11  1  0
 12 11  2  0
 13 12  1  0
 14 13  2  0
 15 14  1  0
 16 15  2  0
 11 16  1  0
 14 17  1  0
 18  3  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 22 21  1  0
  3 22  1  0
 21 23  1  0
 23 24  2  0
 25 24  1  0
 22 25  2  0
M  END

Alternative Forms

  1. Parent:

    ALA5287872

    ---

Associated Targets(Human)

CYP17A1 Tclin Cytochrome P450 17A1 (3627 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP1A2 Tchem Cytochrome P450 1A2 (26471 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 329.34Molecular Weight (Monoisotopic): 329.1077AlogP: 3.87#Rotatable Bonds: 2
Polar Surface Area: 48.01Molecular Species: NEUTRALHBA: 5HBD:
#RO5 Violations: HBA (Lipinski): 5HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 2.19CX LogP: 2.46CX LogD: 2.46
Aromatic Rings: 5Heavy Atoms: 25QED Weighted: 0.49Np Likeness Score: -1.83

References

1. Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A..  (2022)  The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.,  75  [PMID:36031020] [10.1016/j.bmcl.2022.128951]

Source